The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close.

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

A news report from english.shanghai.gov.cn Country Exhibition As a key highlight of the China International Import Expo, the ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...